Assess whether the primary endpoint will survive FDA scrutiny (4ab608)

SITUATION The working file is RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design. 505(b)(2) development lead in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population. 2. RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a pediatric ethicist objecting to the proposed design; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in RWE protocol that may not meet regulator expectations for 505(b)(2) development lead in a mid-size sponsor after a complete response letter. 4. RWE protocol that may not meet regulator expectations is missing the fact 505(b)(2) development lead needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.